[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

4 clusters · 5 sources · 72 days · First seen · Last updated

Intuitive Surgical corporate governance and financial status

Overview

Intuitive Surgical has undergone recent corporate governance updates and experienced fluctuations in its financial performance and stock valuation.

In July 2026, the company implemented changes to its corporate bylaws regarding shareholder nomination rules, voting standards, and special general meeting conditions. During this period, Director Amy Ladd executed a pre-arranged Rule 10b5-1 trading plan to sell 72 shares of stock.

While the company reported strong quarterly earnings—including a revenue increase of approximately 18.4 to 19 percent driven by a rise in worldwide procedures using da Vinci and Ion systems—its stock price faced downward pressure. By early September 2026, shares fell below $370, closing at $366.70 on the Nasdaq. This level was approximately 21.98 percent lower than the previous year’s price and significantly below the average analyst price target of approximately $508.68, despite reported adjusted earnings per share of $2.80.

By late September 2026, shares rose 2.30 percent to $414.50. This recovery followed the release of a meta-analysis regarding the da Vinci platform, which examined over 14 million procedures. The study indicated that da Vinci procedures were associated with a “54 percent lower probability of conversion to open surgery” and approximately four hours shorter hospital stays compared to laparoscopic methods.

In October 2026, the company reported third-quarter revenue of $3.05 billion, exceeding analyst estimates of $2.91 billion, with adjusted profit reaching $3 per diluted share. System sales rose 30 percent to $769 million, supported by the placement of 546 da Vinci robots, including 315 units of the new da Vinci 5 generation. However, the company tightened its 2026 forecast for worldwide da Vinci procedure growth to a midpoint of 14% to 15%. To broaden access, Intuitive plans to roll out an Extended Use Program in the US, pending regulatory approval.

Entities

Intuitive Surgical · Nasdaq · da Vinci · Jamie Samath · Amy Ladd

Timeline

  1. [BUSINESS] 2 sources
    Intuitive Surgical reports third-quarter revenue growth despite lowered forecast

    Intuitive Surgical reported $3.05 billion in Q3 revenue, beating estimates, but tightened its 2026 procedure growth forecast, causing shares to fall.

  2. [BUSINESS] 2 sources
    Intuitive Surgical shares rise amid clinical data and Q2 growth

    Intuitive Surgical shares rose to 414.50 USD on September 28, 2026, supported by strong Q2 revenue growth and a meta-analysis highlighting the clinical benefits of its da Vinci surgical platform.

  3. [BUSINESS] 2 sources
    Intuitive Surgical stock falls below $370 despite strong quarterly earnings

    Intuitive Surgical shares fell below $370 despite Q2 2026 revenue rising 19 percent to $2.89 billion, driven by growth in da Vinci and Ion system procedures.

  4. [BUSINESS] 3 sources
    Intuitive Surgical updates corporate bylaws and reports insider stock sale

    Intuitive Surgical has updated its corporate bylaws regarding shareholder nominations and voting, while Director Amy Ladd executed a pre-arranged sale of 72 shares.

Sources

ad-hoc-news.de · finanznachrichten.de · fool.de · srnnews.com · tradingview.com

This summary has been updated 2 times: see revision history